Alaunos Therapeutics (TCRT) Total Debt (2016 - 2023)

Alaunos Therapeutics has reported Total Debt for 4 years, with the latest figure at $11.0 million in Q1 2023.

• For the quarter ending Q1 2023, Total Debt fell 54.81% year-over-year to $11.0 million; the trailing twelve-month figure through Mar 2023 stood at $11.0 million (down 54.81% YoY), and the FY2022 full-year result was $16.8 million, down 30.49% from the prior year.
• Total Debt for Q1 2023 stood at $11.0 million, down from $16.8 million in the prior quarter.
• The five-year high for Total Debt was $24.5 million in Q2 2022, with the low at $11.0 million in Q1 2023.
• Historically, Total Debt has averaged $21.1 million across 3 years, with a median of $24.1 million in 2021.
• Annual changes were most pronounced in 2022 — Total Debt dropped 6.37% — and 2023, when it tumbled 54.81%.
• Alaunos Therapeutics' Total Debt stood at $24.1 million in 2021, then slumped by 30.49% to $16.8 million in 2022, then plunged by 34.46% to $11.0 million in 2023.
• The last three Total Debt figures came in at $11.0 million (Q1 2023), $16.8 million (Q4 2022), and $22.7 million (Q3 2022), per Business Quant data.